Serum amyloid A protein (SAA) (SAA)

Serum amyloid A (SAA) is a family of apolipoproteins primarily synthesized by the liver during the acute-phase response to inflammation, regulated by cytokines such as IL-1, IL-6, and TNF-alpha (UniProt P0DJI8). In conditions of chronic inflammation, persistently high levels of SAA can lead to its proteolytic cleavage and subsequent aggregation into insoluble amyloid fibrils, resulting in AA amyloidosis (Yamada, 2022). A critical step in this pathogenic process is the interaction between SAA and glycosaminoglycans (GAGs), such as heparan sulfate, which act as a scaffold to promote SAA misfolding and fibrillogenesis (Kull et al., 2015). The SAA–GAG interface is a specific therapeutic target; for instance, the drug eprodisate is a sulfonated molecule designed to mimic GAGs and competitively inhibit SAA binding, thereby preventing fibril deposition in organs like the kidneys (Dember et al., 2007). While eprodisate has been studied for its ability to slow renal decline, the primary clinical management of AA amyloidosis still focuses on reducing SAA production by treating the underlying inflammatory disease with agents like colchicine or IL-6 inhibitors.

Other names

SAA1SAA2Amyloid fibril protein AASerum amyloid A1Serum amyloid A2PIG4

Competitive inhibition of the interaction between Serum amyloid A and glycosaminoglycans to prevent amyloid fibril assembly and deposition.